Inducible T-cell co-stimulatory (ICOS) receptor agonist, GSK3359609, alone and in combination with pembrolizumab: preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC)

Background
- ICOS ligand (ICOSL) and ICOS have been identified as novel targets for cancer immunotherapy.

Study objectives
- Study objective 1: Determine the efficacy and safety of GSK3359609 in combination with pembrolizumab or pembrolizumab alone in patients with HNSCC.
- Study objective 2: Evaluate the efficacy and safety of GSK3359609 in combination with pembrolizumab in patients with HNSCC.

Methods
- Key inclusion criteria:
  - Patients with histologically confirmed HNSCC.
  - PD-L1 > 10% by IHC or ≥ 25% tumor cells positive for PD-1.

Results
- Safety and efficacy data have been collected from the INDUCE-1 trial.
- Preliminary results indicate promising clinical activity in combination with pembrolizumab.

Conclusions
- The combination of GSK3359609 and pembrolizumab shows potential clinical benefit in patients with HNSCC.

References
- Key clinical trial registration: NCT03333214.